(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 August 2022 (04.08.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/162158 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 47/10* (2017.01)
A61K 9/10 (2006.01) *A61P 1/00* (2006.01)
A61K 9/19 (2006.01)

(21) International Application Number:
PCT/EP2022/052073

(22) International Filing Date:
28 January 2022 (28.01.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP2021/052208
29 January 2021 (29.01.2021) EP
PCT/EP2021/082830
24 November 2021 (24.11.2021) EP

(71) Applicant: **ACTELION PHARMACEUTICALS LTD** [CH/CH]; Gewerbestrasse 16, 4123 Allschwil (CH).

(72) Inventors: **AMSSOMS, Katie**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **DE PROOST, Eddy**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **DONG, Wenyu**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **HARTMAN KOK, Paul**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **HOLM, Rene**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **KIMPE, Kristof**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **MEURS, Greet**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **VERSTRAETEN, Maxim**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE).

(74) Agent: **RUHLMANN, Eric**; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123 Allschwil (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

WO 2022/162158 A1

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING A DIPHENYLPYRAZINE DERIVATIVE

(57) Abstract: The present invention relates to a pharmaceutical composition comprising the calcium;{4- [(5,6-diphenylpyrazin-2-yl) (propan-2-yl)amino]butoxy}acetate, in particular to long-acting injectables comprising the same, the use of the pharmaceutical composition for the treatment or prevention of specific diseases, and a process to produce it.